Welocalize buys CRO-focused translation firm Next Level Globalization

Translation firm Welocalize has bought CRO and pharma focused language services organization Next Level Globalization (NLG).

The deal – financial terms of which were not disclosed – was prompted by NLG’s medical technology, diagnostics, biotechnology and pharmaceuticals focused translation businesses, particularly its CRO sector client base.

In addition, NLG claims it is global contract partner for six of the biggest 10 in vitro diagnostics companies in the world.

Welocalize said, “The acquisition of NLG doubles Welocalize's portfolio of leading global brands in the life sciences. NLG has extensive expertise in providing language services to highly regulated companies.

“These services include medical translations and in-country reviews, as well as regulatory advice on software localization. The merger will significantly expand Welocalize's presence in Europe, the central hub of the life sciences industry. This further increases the company's customer availability.”

This was echoed by Nicole Sheehan, Vice President of Customer Success for Regulated Services at Welocalize, who said, “Our experienced team understands the demanding medical technology and diagnostics industry and offers our long-term customers personalized services.”

The acquisition is the nineteenth Germany-based Welocalize has made since it was set up more than a decade ago. The firm said that NLG’s business – particularly in the German market – more than doubles its life sciences business.

Globalization

Clinical trials are a truly global business. In recent decades, difficulties recruiting participants for drug testing in Western markets have prompted sponsors and CROs to include trial sites in regions in untapped markets.

Likewise, the growth of “pharmerging” countries has made them more attractive to international drug companies which – in many cases – has prompted them to conduct local clinical trials to access those markets.

All of which has increased pharma and CRO sector demand for translation services that are able to convert trial protocols into the appropriate local language or languages.

Image; iStock/Devonyu